Skip to main content

Sequenom s Q1 Revenues Surge, Losses Halved

This article has been updated from a previous version, which had the incorrect percentage increase in the first paragraph.


NEW YORK, May 5 (GenomeWeb News) - Sequenom yesterday reported a 61-percent jump in first-quarter revenues and a dramatic reduction in net losses.


For the quarter ended March 31, Sequenom's revenues increased to $6.9 million from $4.3 million in the first quarter of 2005.


The company's net loss for the first quarter was $3.7 million, or $.09 per share, compared to $7.4 million, or $.19 per share for the first quarter of 2005.


Sequenom cut its R&D spending to $2.5 million from $3.3 million in the first quarter of 2005.


On March 31, the company had available cash and short-term investments of $2.9 million.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.